- Home
- OCTO vs HSCS Comparison
OCTO vs HSCS Comparison
Compare OCTO & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCTO
- HSCS
- Stock Information
- Founded
- OCTO 1966
- HSCS 2007
- Country
- OCTO United States
- HSCS United States
- Employees
- OCTO N/A
- HSCS N/A
- Industry
- OCTO
- HSCS Medical Specialities
- Sector
- OCTO
- HSCS Health Care
- Exchange
- OCTO Nasdaq
- HSCS Nasdaq
- Market Cap
- OCTO 4.2M
- HSCS 3.7M
- IPO Year
- OCTO N/A
- HSCS 2022
- Fundamental
- Price
- OCTO $1.18
- HSCS $3.70
- Analyst Decision
- OCTO
- HSCS Strong Buy
- Analyst Count
- OCTO 0
- HSCS 2
- Target Price
- OCTO N/A
- HSCS $13.00
- AVG Volume (30 Days)
- OCTO 13.0K
- HSCS 52.0K
- Earning Date
- OCTO 08-13-2025
- HSCS 07-28-2025
- Dividend Yield
- OCTO N/A
- HSCS N/A
- EPS Growth
- OCTO N/A
- HSCS N/A
- EPS
- OCTO N/A
- HSCS N/A
- Revenue
- OCTO $41,576,562.00
- HSCS N/A
- Revenue This Year
- OCTO N/A
- HSCS N/A
- Revenue Next Year
- OCTO N/A
- HSCS N/A
- P/E Ratio
- OCTO N/A
- HSCS N/A
- Revenue Growth
- OCTO N/A
- HSCS 261.17
- 52 Week Low
- OCTO $0.98
- HSCS $2.36
- 52 Week High
- OCTO $4.86
- HSCS $5.30
- Technical
- Relative Strength Index (RSI)
- OCTO 44.86
- HSCS 46.34
- Support Level
- OCTO $1.17
- HSCS $3.63
- Resistance Level
- OCTO $1.25
- HSCS $3.92
- Average True Range (ATR)
- OCTO 0.07
- HSCS 0.31
- MACD
- OCTO 0.00
- HSCS -0.02
- Stochastic Oscillator
- OCTO 61.90
- HSCS 8.75
About OCTO Eightco Holdings Inc.
Eightco Holdings Inc operates in Forever 8 Inventory Cash Flow Solution. The company is a dynamic technology-focused company committed to driving growth and innovation through strategic acquisitions and management. Forever 8 focuses on purchasing inventory for e-commerce retailers and is part of its Inventory Solution Business.
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.